2023
Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke
Arends C, Liman T, Strzelecka P, Kufner A, Löwe P, Huo S, Stein C, Piper S, Tilgner M, Sperber P, Dimitriou S, Heuschmann P, Hablesreiter R, Harms C, Bullinger L, Weber J, Endres M, Damm F. Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. Blood 2023, 141: 787-799. PMID: 36441964, DOI: 10.1182/blood.2022017661.Peer-Reviewed Original ResearchConceptsComposite end pointPrimary composite end pointRecurrent vascular eventsVascular eventsIschemic strokeClonal hematopoiesisInterleukin-6Risk factorsHigh-sensitivity C-reactive proteinLarge artery atherosclerosis strokeVascular cell adhesion molecule-1Cell adhesion molecule-1Secondary vascular eventsIncident ischemic strokeMultivariable Cox regressionIndependent risk factorC-reactive proteinRisk of atherosclerosisShorter overall survivalMajor risk factorWhite matter lesionsAdhesion molecule-1Peripheral blood DNAPrecision medicine approachIL-6 receptor
2022
Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
Sperber P, Gebert P, Broersen L, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). Journal Of Neurology 2022, 269: 5521-5530. PMID: 35718820, PMCID: PMC9468072, DOI: 10.1007/s00415-022-11203-x.Peer-Reviewed Original ResearchConceptsSeronegative patientsIschemic strokeCognitive functionNMDAR1-ABLow titersHigh titersFavorable cognitive outcomeModerate ischemic strokeAntibody seropositivityProspective cohortReceptor antibodiesSerum titersPatientsSeropositivityCognitive statusStrokeTelephone interviewsInverse probabilityTitersCognitive outcomesCell-based assaysTICSLong termSerostatusResultsData
2020
Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke
Rohmann J, Huo S, Sperber P, Piper S, Rosendaal F, Heuschmann P, Endres M, Liman T, Siegerink B. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. Journal Of Thrombosis And Haemostasis 2020, 18: 3316-3324. PMID: 32935900, DOI: 10.1111/jth.15092.Peer-Reviewed Original ResearchConceptsFirst ischemic strokeIschemic strokeCoagulation factor XIIVascular outcomesHazard ratioRisk factorsActivity levelsFactor XIICox proportional hazards modelIschemic stroke eventsRecurrent vascular eventsWorse vascular outcomesCardiovascular risk factorsIschemic stroke patientsFirst thrombotic eventSecondary eventsProportional hazards modelModerate ischemic stroke patientsFactor activity levelsRecurrent strokeCause mortalityProspective cohortVascular eventsThrombotic eventsStroke events
2019
Direct electrophysiological evidence that spreading depolarization-induced spreading depression is the pathophysiological correlate of the migraine aura and a review of the spreading depolarization continuum of acute neuronal mass injury
Major S, Huo S, Lemale C, Siebert E, Milakara D, Woitzik J, Gertz K, Dreier J. Direct electrophysiological evidence that spreading depolarization-induced spreading depression is the pathophysiological correlate of the migraine aura and a review of the spreading depolarization continuum of acute neuronal mass injury. GeroScience 2019, 42: 57-80. PMID: 31820363, PMCID: PMC7031471, DOI: 10.1007/s11357-019-00142-7.Peer-Reviewed Original ResearchConceptsDepression of activityDirect electrophysiological evidenceMigraine auraNeurological deficitsPathophysiological correlatesGray matterMassive glutamate releaseMassive ion translocationTransient ischemic attackFocal neurological deficitsCerebral amyloid angiopathyAneurysmal subarachnoid hemorrhageElectrophysiological evidenceMass injuryBrain gray matterIschemic attackMigraine strokeDendritic beadingAmyloid angiopathyGlutamate releaseSubarachnoid hemorrhageDirect current potentialNeuronal somataClinical distinctionIschemic tissueSerum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies